³Ô¹ÏÍøÕ¾

Latest AusBiotech News | Page 5

IVDs used in FMT screening exempt from Class 4 IVD requirement
Certa Therapeutics’ FT011 granted US FDA fast track for systemic sclerosis
Inaugural AusMedtechInvest 2024 launched
CSIRO launches free SME programme for medtech and digital health companies
Syntara launches new blood cancer trial of lead candidate
Opthea completes enrolment in first pivotal trial with sozinibercept
CSL reports strong first half growth with immunoglobulins the highlight
Immuron reports record sales of Travelan immune supplement
NSW Women in Life Sciences Luncheon 2024 speakers announced
Cochlear upgrades earnings guidance on better than expected implant revenue
First patient receives treatment in Chimeric’s trial of CHM 0201 in AML
Competition opens to elevate early-stage medtech pitches
Deflexifol clinical data presented at ASCO Gastrointestinal Cancers Symposium
Sustainable funding sought for ³Ô¹ÏÍøÕ¾ One Stop Shop for clinical trials
Cell & Gene Catalyst working groups members announced
Starpharma says Viraleze shows antiviral efficacy in COVID-19 patients
Arovella licences novel CARiNKT cell armouring technology
Pioneering melanoma researchers named 2024 Australian of the Year
AusBiotech members invited to capital attraction roundtable
Aravax closes funding round to accelerate development for peanut allergy therapy
AVITA Medical signs US distribution agreement with Stedical Scientific
Opthea receives additional funding under development funding agreement
Chimeric Therapeutics completes placement with shortfall commitments
Carina Biotech doses first patient in Phase 1/2a trial of LGR5-Targeted CAR-T cell therapy
Neuren Pharmaceuticals announces top-line results of Phase 2 NNZ-2591 trial
Year of collective success: 2023 in review
AusBiotech announces Acting CEO
CMAX Clinical Research preparing to celebrate three decades of continuous operations
Brooker Consulting launches two new initiative for life science sector
AusBiotech calls for journal articles 14 December
FDA grants fast-track designation for EnGeneIC’s pancreatic cancer candidate
Prescient announces the results of PTX-100 Phase 1b study in T-cell lymphoma patients
New leadership for Health Security Systems Australia
Victorian Government backs the development of Cyban’s brain injury technology
Australia’s clinical trial sector connects at AusBiotech 2023
AusBiotech energised by new Board appointments
Cynata Therapeutics secures approval for Phase 2 trial in Turkey
Microba Life Sciences announces results of successful Phase IBD trial
Telix says the first patient dosed in European early access program for TLX250-CDx
Neuren Pharmaceuticals completes enrolment in Pitt Hopkins syndrome Phase 2 trial
Australia’s Cell and Gene Catalyst calls for Expressions of Interest
OncoSil Medical onboards first patient in the PANCOSIL clinical trial
Korean regulator approves Amplia Therapeutics’ pancreatic cancer trial
Clarity’s theranostic prostate cancer trial progresses at the highest dose level cohort
Microba completes stage one screening for its autoimmune disease program
³Ô¹ÏÍøÕ¾ Reconstruction Fund (NRF) investment mandate released
Federal government backs the development of treatment for childhood brain cancer
Dimerix’s ACTION3 investigational new drug approved in China